http://www.amgennews.com/index.php en pmannle@amgen.com Copyright 2012 2012-04-25T16:50:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_acquire_mustafa_nevzat_a_leading_privately_held_turkish_pharmaceut/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_acquire_mustafa_nevzat_a_leading_privately_held_turkish_pharmaceut/#When:16:50:00Z Acquisition Will Build on Amgen’s Existing Business and Provide a Platform for Growth in Turkey and This Strategically Important Region THOUSAND OAKS, Calif. and ISTANBUL, April 25, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN), the world’s largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (MN) today announced an agreement under which Amgen will acquire 95.6 percent of shares in MN, a privately held Turkish pharmaceutical company, for an amount that values MN at US $700 million.  The all-cash transaction will significantly expand Amgen’s presence in Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen. Press Releases 2012-04-25T16:50:00+00:00 http://www.amgennews.com/index.php/2008NewsService/a_tribute_to_george_rathmann_amgens_founding_ceo_1927_2012/ http://www.amgennews.com/index.php/2008NewsService/a_tribute_to_george_rathmann_amgens_founding_ceo_1927_2012/#When:16:24:00Z THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away. Press Releases 2012-04-23T16:24:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2012_first_quarter_financial_results/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2012_first_quarter_financial_results/#When:16:34:00Z THOUSAND OAKS, Calif., April 19, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 24, 2012, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m.  Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and CEO, and other members of Amgen’s senior management team. Press Releases 2012-04-19T16:34:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_acquire_privately_held_kai_pharmaceuticals/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_acquire_privately_held_kai_pharmaceuticals/#When:17:14:01Z Acquisition Includes KAI-4169 Program, Which Delivered Compelling Phase 2a Clinical Results for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease who are on Dialysis THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.  KAI’s lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis.  SHPT, a component of CKD mineral and bone disorder (MBD), is a common and serious complication for patients with CKD who are on dialysis.  Through this acquisition, Amgen will acquire worldwide rights, excluding Japan, to KAI-4169. Press Releases 2012-04-10T17:14:01+00:00 http://www.amgennews.com/index.php/2008NewsService/ucb_and_amgen_initiate_sclerostin_antibody_phase_3_program_in_patients_with/ http://www.amgennews.com/index.php/2008NewsService/ucb_and_amgen_initiate_sclerostin_antibody_phase_3_program_in_patients_with/#When:17:12:00Z First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis. Press Releases 2012-04-03T17:12:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_and_astrazeneca_announce_collaboration_to_jointly_develop_and_commerc/ http://www.amgennews.com/index.php/2008NewsService/amgen_and_astrazeneca_announce_collaboration_to_jointly_develop_and_commerc/#When:20:57:00Z Collaboration Comprises Five Monoclonal Antibodies Brodalumab (AMG 827) Phase 3 Trial Planned in 2012 THOUSAND OAKS, Calif. and LONDON, April 2, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen’s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)). Press Releases 2012-04-02T20:57:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_phase_2_study_results_for_brodalumab_in_moderate_to_severe_/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_phase_2_study_results_for_brodalumab_in_moderate_to_severe_/#When:21:35:00Z Brodalumab Moving Into Phase 3 for Moderate to Severe Psoriasis THOUSAND OAKS, Calif., March 28, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine. The 12-week, dose-ranging study achieved its primary endpoint with the mean percentage improvement in psoriasis area and severity index (PASI) score higher in all brodalumab groups compared to placebo (p<0.001).  Brodalumab is a human monoclonal antibody that selectively binds to and blocks signaling via the interleukin-17 (IL-17) receptor, thereby stopping the binding of several IL-17 family members associated with psoriasis. The majority of subjects treated with brodalumab 210 mg every other week achieved total clearance of their skin disease (PASI 100 of 62 percent). Press Releases 2012-03-28T21:35:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgens_pcsk9_inhibitor_reduced_ldl_cholesterol_up_to_81_percent_in_phase_1b/ http://www.amgennews.com/index.php/2008NewsService/amgens_pcsk9_inhibitor_reduced_ldl_cholesterol_up_to_81_percent_in_phase_1b/#When:21:00:00Z Robust AMG 145 Phase 2 Program Expected to Deliver Results in 2012 THOUSAND OAKS, Calif., March 25, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001).  The cholesterol lowering effects of AMG 145 were similar among patients on high doses of statins (80 mg atorvastatin and 40 mg rosuvastatin) and patients on low to moderate doses of statins. No deaths or serious adverse events (AEs) were reported in the study. Full results of the study were presented for the first time today in an oral session at the American College of Cardiology Scientific Session in Chicago.  (Abstract # 923-4) Press Releases 2012-03-25T21:00:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_2012_second_quarter_dividend/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_2012_second_quarter_dividend/#When:16:42:00Z THOUSAND OAKS, Calif., March 15, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the second quarter of 2012. The dividend will be paid on June 7, 2012, to all stockholders of record as of the close of business on May 16, 2012. Press Releases 2012-03-15T16:42:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_completes_tender_offer_for_outstanding_shares_of_micromet_inc/ http://www.amgennews.com/index.php/2008NewsService/amgen_completes_tender_offer_for_outstanding_shares_of_micromet_inc/#When:00:18:00Z THOUSAND OAKS, Calif., March 7, 2012 /PRNewswire/ -- Amgen Inc.  ("Amgen") (NASDAQ:AMGN) announced today the expiration of the subsequent offering period of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub," to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ:MITI) for $11.00 per share in cash.  The subsequent offering period expired at 12:00 midnight, New York City time, at the end of Tuesday, March 6, 2012.  Press Releases 2012-03-07T00:18:00+00:00